When will the next total solar eclipse be visible in the UK?
On 2 August, 2027, parts of southern Europe will see a total solar eclipse.
It won;t be quite as spectacular in the UK. Londoners will experience a 42% eclipse - with the sun appearing as a crescent. People in the Scilly Isles will see a partial eclipse of 48%, while those in the Shetlands will see a 13% eclipse.
In a partial eclipse, the sky will not go dark, but shadows might look different, and the sun is visibly 'blocked' by the moon - while a total eclipse offers a few minutes of darkness which often provokes audible gasps.
The total eclipse will see areas such as the Straits of Gibraltar, North Africa and the Arabian Peninsula, with up to six minutes, 23 seconds of 'totality'. Luxor in Egypt and Mecca in Saudi Arabia are among the areas on the path of totality, according to Sky at Night magazine.
Despite online reports this week, which possibly mixed up the events in 2027, there is most definitely no eclipse in August 2025 - the only eclipse this year came earlier, when the UK saw a partial eclipse with up to 30% eclipse on 29 March 2025.
When will the next total solar eclipse be in the UK?
Next year will see a partial eclipse on 12 August, 2026, with the eclipse peaking at 96% in the Scilly Isles. Most areas in the UK will see an 89% eclipsed sun.
But if you're waiting for a proper total solar eclipse in the UK, you're in for rather a long wait (and it will also help to be young at this point) as the next one will not be until 23 September, 2090, when it will be visible from southern England and southern Ireland.
What happens during a total solar eclipse?
Total solar eclipses happen when the moon completely covers the sun, and is only visible from a certain area (known as 'the path of totality').
Areas nearby witness a partial eclipse instead.
The reason it happens is that the moon is 400 times smaller than the sun, and also 400 times closer to us than the Sun (by complete coincidence), so that they appear 'the same size' at the time of an eclipse.
In the darkest part of the shadow, the Sun's light is almost completely blocked out.
NASA says, 'People viewing the eclipse from locations where the Moon's shadow completely covers the Sun – known as the path of totality – will experience a total solar eclipse. The sky will become dark, as if it were dawn or dusk.
'Weather permitting, people along the path of totality will see the Sun's corona, or outer atmosphere, which is usually obscured by the bright face of the Sun.'
Some observers report feeling a chill, and birds stopping singing because they think it's night time.
The last total solar eclipse in the UK was in 1999, although it was only visible from Cornwall and the Scilly isles, according to the Royal Observatory.
Patchy weather meant that only some eclipse-watchers got a good sight of the eclipse (and some were soaked with rain instead).
The Guardian describes how 'gasps of amazement' rang out in Penzance as totality descended for two minutes and six seconds.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark Preston as Chief Technology Officer (CTO). These strategic appointments strengthen Llusern's leadership team as the company builds on its recent ISO 13485 certification and progresses towards IVDR certification, positioning Lodestar DX for upcoming commercial launches across Europe for treatment-directing diagnosis of urinary tract infections (UTIs). Bob Yang joins Llusern Scientific as Chief Medical Officer. A highly accomplished urology consultant, Mr. Yang brings extensive expertise in complex and recurrent UTIs and male and female incontinence. He has made significant contributions to antibiotic-free treatment options for recurrent UTIs and has been pioneering research in sub-lingual UTI vaccines and male incontinence devices. His expertise will directly complement Llusern's mission to revolutionize UTI diagnostics and support antimicrobial stewardship through the Lodestar DX system, a rapid diagnostic platform designed to enhance clinical decision-making. He is Lead Editor for Springer Nature academic textbooks on Urinary Tract Infections and Male Incontinence, solidifying his standing as one of the global leaders in urological research and practice. Mr. Yang continues to pioneer in his field as a urology consultant at the Royal Berkshire NHS Foundation Hospital and an Associate Lecturer at Oxford University. 'Joining Llusern Scientific is an exciting opportunity to contribute to the growth of innovative diagnostic solutions that will improve patient outcomes globally,' said Bob Yang, Chief Medical Officer of Llusern Scientific. 'The Lodestar DX system offers clinicians a powerful tool to make precise treatment decisions in a single visit, thereby enabling them to combat antimicrobial resistance through improved antibiotic stewardship.' As Chief Financial Officer, Maddy Kennedy brings over 25 years of experience in financial strategy, investor relations, and corporate governance to Llusern Scientific. She will play a crucial role in supporting Llusern's fundraising activities and steering its expansion into global markets. Known for her ability to translate complex development programs into clear financial plans, Maddy has successfully guided life sciences and technology businesses through strategic growth, M&A, IPOs, and exit planning. Her leadership roles at companies such as Maxwellia, Kesmalea Therapeutics, and Psioxus Therapeutics have equipped her with expertise in scaling operations and securing funding. She brings strong governance expertise from Non-Executive Director roles at Nuformix plc, Heartbeat CIC, and Tetris Pharma. She is currently also CFO at PBD Biotech and Fermtech. 'I am excited to join Llusern Scientific at this crucial stage of its development,' said Maddy Kennedy, Chief Financial Officer of Llusern Scientific. 'With its innovative Lodestar DX system poised for expansion into new markets, I look forward to supporting Llusern's growth and overseeing the financial operations needed to achieve its global ambitions.' Mark Preston joins Llusern Scientific as Chief Technology Officer, bringing extensive expertise in biotech, data analytics, and cloud technologies. As CTO, Mark will lead the development of Lodestar DX overseeing technological innovation, scalability, and compliance. Mark's early career includes experience in embedded systems and devices at Sony and Panasonic, working on networking hardware, mobile phones, and microscopes. His later work in app development, AI-driven insights, and workflow optimization enabled him to deliver scalable, secure, and compliant solutions for start-ups and global organizations, including vaccine manufacturers. As a Founder and Managing Director of consultancy firm Prismea, Mark helps biotech companies innovate with data analytics, cloud systems, and regulatory compliance as well as navigating medical regulatory frameworks with organizations such as the MHRA. 'I've been impressed by the Lodestar DX system and its ability to deliver treatment directing diagnosis of UTIs at the point of care,' said Mark Preston, Chief Technology Officer. 'I look forward to supporting the company's efforts to bring precision diagnostics to healthcare settings worldwide.' Emma Hayhurst, Co-founder and CEO of Llusern Scientific, commented:'We are thrilled to welcome Bob, Maddy, and Mark to our executive leadership team. Their deep expertise in urology, finance, and technology will be instrumental in ensuring Llusern remains at the forefront of providing precise, accessible diagnostic solutions that deliver improved outcomes for patients suffering from UTIs.' Notes to Editors About Llusern ScientificLlusern Scientific is a treatment-directing molecular diagnostics company, developing fast, accurate, and accessible tools to guide real-time clinical decision-making at the point-of-care. Our flagship solution, Lodestar DX, is a portable diagnostic device that delivers lab-accurate results for urinary tract infections (UTIs) in around half an hour. It is based on isothermal LAMP technology (not PCR) without the need for DNA extraction or centralized lab infrastructure. With industry-leading sensitivity and specificity, Lodestar DX empowers clinicians to diagnose and treat specific microbial infections with precision in a single visit, thereby improving patient outcomes. As well as providing guidance on the best treatment option based on the specific microbial infection, Lodestar DX also provides a clear 'rule-out' decision where antibiotics are not necessary, helping to reduce antimicrobial resistance through antibiotic stewardship. Building on success in the UK, Llusern is preparing for commercial launches across India and the MENA region in 2025 and the US in 2026. Llusern is committed to transforming diagnostic pathways and making precision medicine equitable, portable, and fast. Due to its small size and ease of portability Lodestar DX is particularly suitable for resource limited and decentralised healthcare settings including care homes, mobile diagnostics, and community diagnostic centres. Additionally Lodestar DX has uses within paediatrics, urology, and other secondary care settings. The Lodestar DX UTI testing system has been independently evaluated in studies by University of Oxford, Norfolk and Norwich University Hospital, Southampton University, and Public Health Wales. The company was established in 2020 as a spin-out from the University of South Wales, UK. For more information, visit and follow us on LinkedIn. Media Contacts Llusern ScientificMartyn Lewis +44 (0) 7825 708936martyn@ Scius CommunicationsKatja Stout +44 (0) 7789435990katja@ Daniel Gooch +44 (0) 7747875479daniel@ in to access your portfolio
Medscape
2 hours ago
- Medscape
QoL Deserves More Than a Footnote in Cancer Trials
In a review published in New England Journal of Medicine Evidence , Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life (QoL) data. 'QoL data are increasingly being included in oncology trials,' Di Maio told Univadis Italy, a Medscape Network platform. 'However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.' With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the European Society For Medical Oncology guidelines on the use of patient-reported outcome measures in oncology, views this as a significant gap in the field. 'We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,' he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit. From Trial Design... To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself. Speaking with Univadis Italy , he also addressed the potential for bias in QoL data collection. 'Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,' he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One coordinated analysis, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data. ...To Data Interpretation Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients' unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. 'QoL data alone aren't sufficient,' Di Maio emphasized, 'but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.' He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.
Yahoo
2 hours ago
- Yahoo
Parkinson's Disease Has a Smell That Some Dogs Can Detect
Dogs really can be trained to smell Parkinson's disease, according to new research from the United Kingdom. In a double blind trial, a Golden Retriever and a Labrador were able to sniff out which skin swabs came from people with Parkinson's. The smell of the oily secretions seemed to hold secret clues. "The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," says animal behavioral scientist Nicola Rooney from the University of Bristol. "Sensitivity levels of 70 percent and 80 percent are well above chance, and I believe that dogs could help us to develop a quick, non-invasive, and cost-effective method to identify patients with Parkinson's disease." Related: Today, there is no definitive early test for Parkinson's, which is why scientists are so interested in finding potential biomarkers of the disease on our skin. The knowledge that Parkinson's distinctly changes a person's body odor first came to light roughly a decade ago – all because of one woman. Twelve years before her husband's diagnosis of Parkinson's disease, Joy Milne could sense something was off – specifically, she could smell it. Milne, a Scottish nurse, is known as a 'super-smeller', and in 2016, she became famous among neuroscientists for her extraordinary abilities. In a small pilot study, Milne correctly identified each patient with Parkinson's disease based solely on the scent of their shirts. Her one misidentification turned out to be correct nearly a year later. The news raised an important question: If someone like Milne could smell Parkinson's years before it was diagnosed, could a dog do the same? Dogs are known to have incredible senses of smell, far more powerful than our own. Previous studies have found our pets can smell our stress, our coronavirus infections, and even our cancers – so if a distinct odor for Parkinson's does exist, then maybe a dog can sniff it out, too. In the past decade, a few preliminary trials have provided evidence for that hypothesis. But some only gave limited information on how the dogs were trained and tested. The recent trial from the UK is a collaboration between a program called Medical Detection Dogs and neuroscientists at the University of Manchester. One goal of the research is to figure out what the dogs are actually smelling, and why. In 2019, for instance, researchers at Manchester helped identify which odor compounds set the distinctive smell of Parkinson's apart. Their results were later confirmed by Milne, the serendipitous "super-smeller". A few years on, the odor compounds were used to create a diagnostic 'swab test' for Parkinson's, currently in testing. Perhaps, further down the road, trained dogs could help neuroscientists identify more unique biomarkers of the disease. The trouble is, though, not all canines are up to snuff. In the current trial, only 2 out of 10 dogs made it through training, and neither performed perfectly. One dog, for instance, falsely flagged a tenth of the odor swabs from healthy people as having Parkinson's. The other gave false alarms less than 2 percent of the time. Overall, however, the dogs could smell which person had Parkinson's at a rate well above chance, providing proof of principle. "We are extremely proud to say that once again, dogs can very accurately detect disease," says Claire Guest, the CEO of Medical Detection Dogs. "There is currently no early test for Parkinson's disease and symptoms may start up to 20 years before they become visible and persistent leading to a confirmed diagnosis. "Timely diagnosis is key… " The study was published in the Journal of Parkinson's Disease. Related News Expert Reveals What Can Happen if Testosterone Gel Rubs Onto Others Radioactive Waste Exposed Children in Missouri to Cancer Risks, Study Finds A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging Solve the daily Crossword
